News Release

Non-Brokered Private Placement

Date: September 8, 2000

CDNX Trading Symbol: WXI
World Wide Web: http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc. (the "Company") announces the setting of a non-brokered private placement for 200,000 common shares at $2.17 per share with 2-year warrant attached for 200,000 shares exercisable at $2.55 per share in the first year and $3.06 per share in the second year, expiring two years from the closing of the private placement. The proceeds of this private placement will be allocated toward the Research & Development of Tetrodin. The terms of this private placement is subject to approval by regulatory bodies.

Tetrodin has been developed by the Company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The Company has also begun tests on the usage of Tetrodin as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Canadian Venture Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.